Companies/Cronos Group Inc.

Company profile

Cronos Group Inc.

NASDAQ: CRON · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Stayner, ONCIK 0001656472Reports USD

#311 of 1,394 Healthcare companies by revenue70th-percentile growth

EA Score

69B

FH 76DQ 59GM 70SS 68

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, disclosure history

Methodology →

Revenue TTM

$205.7M

Rev growth YoY (TTM)

+65.1%

Net income (FY)

-$9.4M

Employees

459

Market cap

$1.1B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$146.6M$146.6M2025

Net income-$9.4M-$9.4M2025

Operating income-$17.4M-$17.4M2025

Total assets$1.2B$1.2B2025

Liabilities$54.2M$54.2M2025

Equity$1.1B$1.1B2025

Revenue trend

FY2019 – FY2025 · USD

$5.8M

FY19

$23.8M

FY19

$46.7M

FY20

$74.4M

FY21

$91.9M

FY22

$87.2M

FY23

$117.6M

FY24

$146.6M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Cannabis Flower74%

Cannabis Extracts26%

Product and Service, Other0%

By geography

CANADA62%

ISRAEL29%

Other Countries10%

The read

Cronos Group Inc. booked $146.6M in FY2025 revenue, growing 25% year over year — faster than most Healthcare companies we track, at a -6.4% net margin.

Peers · Healthcare

Capricor Therapeutics, Inc.58C GoodRx Holdings, Inc.68B Cullinan Therapeutics, Inc.51D Certara, Inc.68B

Key facts

CEOMichael Ryan Gorenstein

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersStayner, ON

ExchangeNASDAQ: CRON

Employees459

IPO date2018-02-27

Latest filings

8-K2026-06-22 8-K2026-05-11 10-Q2026-05-11 DEF 14A2026-04-24 10-K2026-02-26 8-K2026-02-26 8-K2025-12-09 10-Q2025-11-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.